Anticorps anti-cytoplasme des polynucléaires neutrophiles : Questions médicales fréquentes
Nom anglais: Antibodies, Antineutrophil Cytoplasmic
Descriptor UI:D019268
Tree Number:D23.101.050
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-cytoplasme des polynucléaires neutrophiles : Questions médicales les plus fréquentes",
"headline": "Anticorps anti-cytoplasme des polynucléaires neutrophiles : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Anticorps anti-cytoplasme des polynucléaires neutrophiles : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-07",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Anticorps anti-cytoplasme des polynucléaires neutrophiles"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Marqueurs biologiques",
"url": "https://questionsmedicales.fr/mesh/D015415",
"about": {
"@type": "MedicalCondition",
"name": "Marqueurs biologiques",
"code": {
"@type": "MedicalCode",
"code": "D015415",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.101"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"alternateName": "Antibodies, Antineutrophil Cytoplasmic",
"code": {
"@type": "MedicalCode",
"code": "D019268",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ulrich Specks",
"url": "https://questionsmedicales.fr/author/Ulrich%20Specks",
"affiliation": {
"@type": "Organization",
"name": "Mayo Clinic, Rochester, Minnesota."
}
},
{
"@type": "Person",
"name": "Zachary S Wallace",
"url": "https://questionsmedicales.fr/author/Zachary%20S%20Wallace",
"affiliation": {
"@type": "Organization",
"name": "Massachusetts General Hospital, Boston."
}
},
{
"@type": "Person",
"name": "Xiaoqing Fu",
"url": "https://questionsmedicales.fr/author/Xiaoqing%20Fu",
"affiliation": {
"@type": "Organization",
"name": "Massachusetts General Hospital, Boston."
}
},
{
"@type": "Person",
"name": "Yuqing Zhang",
"url": "https://questionsmedicales.fr/author/Yuqing%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Massachusetts General Hospital, Boston."
}
},
{
"@type": "Person",
"name": "John H Stone",
"url": "https://questionsmedicales.fr/author/John%20H%20Stone",
"affiliation": {
"@type": "Organization",
"name": "Massachusetts General Hospital, Boston."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians.",
"datePublished": "2024-06-14",
"url": "https://questionsmedicales.fr/article/39131917",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.xkme.2024.100858"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of atypical anti-neutrophil cytoplasmic antibody with comorbidities and outcome in a hospital-based population.",
"datePublished": "2024-01-06",
"url": "https://questionsmedicales.fr/article/38234907",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heliyon.2024.e24105"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Changing Anti-Neutrophil Cytoplasmic Antibody Profile in a Patient With a Diagnosis of Eosinophilic Granulomatosis With Polyangiitis.",
"datePublished": "2023-08-28",
"url": "https://questionsmedicales.fr/article/37692370",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14740/jmc4088"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis.",
"datePublished": "2023-03-04",
"url": "https://questionsmedicales.fr/article/36878421",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clim.2023.109274"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oral manifestations of anti-neutrophil cytoplasmic antibody-associated vasculitis: an update and narrative review of the literature.",
"datePublished": "2022-12-05",
"url": "https://questionsmedicales.fr/article/36639252",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.oooo.2022.11.013"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Marqueurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D015415"
},
{
"@type": "ListItem",
"position": 4,
"name": "Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"item": "https://questionsmedicales.fr/mesh/D019268"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Anticorps anti-cytoplasme des polynucléaires neutrophiles - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Comment diagnostiquer la présence d'ANCA ?\nQuels tests sont utilisés pour les ANCA ?\nLes ANCA sont-ils toujours présents dans les maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?\nLes ANCA peuvent-ils être détectés chez des personnes saines ?",
"url": "https://questionsmedicales.fr/mesh/D019268?page=28#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Quels sont les symptômes associés aux ANCA ?\nLes ANCA provoquent-ils des symptômes respiratoires ?\nY a-t-il des symptômes cutanés liés aux ANCA ?\nLes ANCA affectent-ils les reins ?\nLes symptômes des ANCA sont-ils similaires à d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D019268?page=28#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Peut-on prévenir les maladies liées aux ANCA ?\nLes vaccinations sont-elles recommandées pour les patients ANCA ?\nComment réduire le risque de complications ?\nL'évitement de certains médicaments est-il conseillé ?\nLe stress influence-t-il les maladies ANCA ?",
"url": "https://questionsmedicales.fr/mesh/D019268?page=28#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Quels traitements sont utilisés pour les ANCA ?\nLes traitements sont-ils personnalisés pour chaque patient ?\nLes ANCA nécessitent-ils un suivi régulier ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements peuvent-ils guérir les ANCA ?",
"url": "https://questionsmedicales.fr/mesh/D019268?page=28#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Quelles sont les complications possibles des ANCA ?\nLes ANCA peuvent-ils entraîner des infections ?\nY a-t-il un risque de cancer associé aux ANCA ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications des ANCA ?",
"url": "https://questionsmedicales.fr/mesh/D019268?page=28#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Anticorps anti-cytoplasme des polynucléaires neutrophiles",
"description": "Quels sont les facteurs de risque des ANCA ?\nLe sexe influence-t-il le risque d'ANCA ?\nL'âge joue-t-il un rôle dans le développement des ANCA ?\nCertaines professions augmentent-elles le risque d'ANCA ?\nLes infections antérieures sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D019268?page=28#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la présence d'ANCA ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test sanguin spécifique détecte les ANCA dans le sérum du patient."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les ANCA ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et indirect immunofluorescence sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les ANCA sont-ils toujours présents dans les maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur présence varie selon la maladie et le stade de l'inflammation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique aide à identifier les symptômes et les antécédents de maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les ANCA peuvent-ils être détectés chez des personnes saines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ANCA peuvent être présents à faible niveau chez des individus sains."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes associés aux ANCA ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, perte de poids et douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Les ANCA provoquent-ils des symptômes respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent causer des symptômes respiratoires comme la toux et l'essoufflement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés liés aux ANCA ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des lésions peuvent apparaître chez certains patients."
}
},
{
"@type": "Question",
"name": "Les ANCA affectent-ils les reins ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner des atteintes rénales, comme la glomérulonéphrite."
}
},
{
"@type": "Question",
"name": "Les symptômes des ANCA sont-ils similaires à d'autres maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être confondus avec d'autres maladies auto-immunes ou inflammatoires."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux ANCA ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain aide."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées pour les patients ANCA ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent être recommandées pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de complications ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et une gestion proactive des symptômes sont essentiels."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments est-il conseillé ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aggraver les symptômes et doivent être évités."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les maladies ANCA ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver les symptômes et doit être géré efficacement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour les ANCA ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les corticostéroïdes et les immunosuppresseurs sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés pour chaque patient ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est adapté en fonction de la gravité et des symptômes du patient."
}
},
{
"@type": "Question",
"name": "Les ANCA nécessitent-ils un suivi régulier ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller l'évolution."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent avoir des effets secondaires comme l'infection ou l'ostéoporose."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils guérir les ANCA ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de cure, mais les traitements peuvent contrôler les symptômes et la progression."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des ANCA ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des atteintes rénales, pulmonaires et cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les ANCA peuvent-ils entraîner des infections ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements immunosuppresseurs augmentent le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de cancer associé aux ANCA ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un risque accru de certains cancers chez les patients ANCA."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications des ANCA ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des tests sanguins aident à surveiller les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des ANCA ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque d'ANCA ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont plus souvent touchées par les maladies associées aux ANCA."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le développement des ANCA ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les ANCA apparaissent généralement chez les adultes jeunes à moyens d'âge."
}
},
{
"@type": "Question",
"name": "Certaines professions augmentent-elles le risque d'ANCA ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les professions exposant à des produits chimiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections antérieures sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher la production d'ANCA chez des individus prédisposés."
}
}
]
}
]
}
Research in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) has focused on reducing treatment toxicities, notably through reduction of exposure to glucocorticoids. Glucocorticoid-spar...
International, online survey....
Clinicians in various countries with experience in managing vasculitis....
Survey questions to gauge interest and preferences in studying an induction of remission regimen for severe AAV using only 2 or 4 weeks of glucocorticoids without avacopan. Data collected included gen...
Using a 10-point Likert scale, respondents ranked each candidate trial on its usefulness in demonstrating whether a minimal glucocorticoid regimen would be safe and effective and their willingness to ...
There were 210 respondents to the survey. The candidate trials were rated moderate-to-high for usefulness to demonstrate safety and efficacy (scores 6-7/10), and moderate (scores 5-6/10) for willingne...
Representativeness of survey sample and generalizability of findings....
Combination cyclophosphamide-rituximab may be the ideal way of studying minimal glucocorticoid use in severe AAV. Given its increasing uptake, incorporating avacopan into a potential trial design is i...
Atypical anti-neutrophil cytoplasmic antibody (a-ANCA) is characterized by a positive fluorescence staining other than typical cytoplasmic or perinuclear ANCA. ANCA is associated with increased risk o...
This retrospective study enrolled 164 and 170 patients with typical ANCA and a-ANCA positivity, respectively, who visited Taichung Veterans General Hospital, Taiwan from January 2016 to March 2021. Lo...
Patients with a-ANCA had lower chance of ANCA-associated vasculitis (OR: 0.02, 95 % CI: 0.01-0.07...
Patients with a-ANCA had better renal survival and lower mortality rates compared to patients with typical ANCA. These real-world data provide evidence of the long-term outcome and shed light on avenu...
This report describes a hitherto unique case of eosinophilic granulomatosis with polyangiitis (EGPA), a subtype of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The patient was an ...
Levels of neutrophil extracellular traps (NETs) were measured in plasma of healthy controls (HC, n = 30) and patients with granulomatosis with polyangiitis (GPA, n = 123), microscopic polyangiitis (MP...
Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a multisystem disorder of small blood vessels subdivided into granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA)...
This study aimed to evaluate the predictive value of the neutrophil-to-lymphocyte ratio (NLR) for infection in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)....
Newly onset patients with AAV in China were included, and their laboratory tests and disease activity were analyzed. Based on infection, patients were divided into the infection group (A-I) and the no...
In total, 418 patients were enrolled. Significantly higher white blood cell count (WBC, p < 0.001), neutrophils (p < 0.001), NLR (p < 0.001), platelet-to-lymphocyte ratio (p < 0.001), monocyte-to-lymp...
Our study demonstrated that in addition to WBC, CRP, ESR, and PCT, NLR should also be used as a beneficial inflammatory indicator to differentiate infection in newly diagnosed AAV. Key Points • NLR wa...
A 62-year-old woman presented with a chronic fever and fatigue. Biological investigations showed leukocytosis and elevation of acute phase markers. Liver blood tests showed deterioration with both cho...
Anti-Neutrophil Cytoplasmic Antibody associated Vasculitides (AAV) comprise a rare group of disorders in which respiratory tract involvement is variable and often severe. The rarity and heterogeneity ...
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare multisystem autoimmune disease resulting from necrotizing inflammation of small vessels. Genetic predisposition and environm...
Here we describe a facile and robust genetic selection for isolating full-length IgG antibodies from combinatorial libraries expressed in the cytoplasm of redox-engineered Escherichia coli cells. The ...